Revance Therapeutics Inc at Stifel Virtual Healthcare Conference Transcript
Hi, good afternoon, everyone, and welcome to the Revance presentation. I am Annabel Samimy, biopharmaceutical analyst here at Stifel. And it's our pleasure to have Mark Foley with us today, CEO of Revance, as well as Toby Schilke, who is somewhere in a box I think on this platform.
So, as we look at Revance today, you are literally jumping into a commercial transition with the launch of your aesthetics platform that includes both fillers and a fintech platform, and you are about to add another with -- I'm going to stay within six months because we're not quite sure. So, why don't I just step back, let you guys have a five minute state of affairs -- brief state of affairs of where Revance is right now and we'll just launch into Q&A.
Sounds good. Thanks, Annabel. We really appreciate the opportunity to be here. So, I think just stepping back, this has been truly a transformational year for Revance. If you think of where we were this time last year,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |